Low serum level of epidermal growth factor in chronic ketamine users
Background Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls...
Gespeichert in:
| Veröffentlicht in: | Human psychopharmacology 2018-05, Vol.33 (3), p.e2656-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e2656 |
| container_title | Human psychopharmacology |
| container_volume | 33 |
| creator | Zhang, Minling He, Hongbo Ning, Yuping Ding, Yi Ke, Xiaoyin Wang, Daping Deng, Xuefeng Fan, Ni |
| description | Background
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and psychopathological symptoms were analyzed.
Methods
Sixty‐seven chronic ketamine users and 40 healthy subjects were recruited. Serum EGF levels were measured by enzyme‐linked immunosorbent assay. Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale, Beck Depression Inventory and Beck Anxiety Inventory.
Results
The serum level of EGF in the chronic ketamine users was significantly lower than that of healthy subjects (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml, F = 15.169, p |
| doi_str_mv | 10.1002/hup.2656 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2020491388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2047407085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3106-54e1288372340985e94fb3c1d7d89a2bef063d669935bcc1b6b6dd0a162c896f3</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK2Cv0AWvHhJnd0km92j1I8KBT3Yc0g2E5uaZOtuYum_d2urguBpYOaZZ4aXkHMGYwbArxf9asxFLA7IkIFSAYMkOSRDkDIOBOd8QE6cWwL4GahjMuBKgG_LIbmdmTV1aPuG1viBNTUlxVVVoG2ymr5as-4WtMx0ZyytWqoX1rSVpm_YZU3VIu39rjslR2VWOzzb1xGZ39-9TKbB7OnhcXIzC3TIQARxhIxLGSY8jEDJGFVU5qFmRVJIlfEcSxBhIYRSYZxrzXKRi6KAjAmupRJlOCJXO-_KmvceXZc2ldNY11mLpncpBw6RYqG_MSKXf9Cl6W3rv_NUlESQgIx_hdoa5yyW6cpWTWY3KYN0m2zqk023yXr0Yi_s8waLH_A7Sg8EO2Bd1bj5V5RO589fwk8WdIA5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047407085</pqid></control><display><type>article</type><title>Low serum level of epidermal growth factor in chronic ketamine users</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Zhang, Minling ; He, Hongbo ; Ning, Yuping ; Ding, Yi ; Ke, Xiaoyin ; Wang, Daping ; Deng, Xuefeng ; Fan, Ni</creator><creatorcontrib>Zhang, Minling ; He, Hongbo ; Ning, Yuping ; Ding, Yi ; Ke, Xiaoyin ; Wang, Daping ; Deng, Xuefeng ; Fan, Ni</creatorcontrib><description>Background
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and psychopathological symptoms were analyzed.
Methods
Sixty‐seven chronic ketamine users and 40 healthy subjects were recruited. Serum EGF levels were measured by enzyme‐linked immunosorbent assay. Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale, Beck Depression Inventory and Beck Anxiety Inventory.
Results
The serum level of EGF in the chronic ketamine users was significantly lower than that of healthy subjects (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml, F = 15.169, p < 0.01). The serum EGF level was negatively correlated with the current average dose of ketamine consumption per day of use (p = 0.015), and positively associated with the Positive and Negative Syndrome Scale positive symptom score (p = .022).
Conclusions
Serum level of EGF decreased in chronic ketamine users compared with healthy subjects, which may play a role in the pathophysiology of ketamine related disorders.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.2656</identifier><identifier>PMID: 29602228</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Anxiety ; Demographics ; Epidermal growth factor ; Epidermal Growth Factor - blood ; Excitatory Amino Acid Antagonists - adverse effects ; Female ; Growth factors ; Humans ; Ketamine ; Ketamine - adverse effects ; Male ; Mental depression ; serum ; Serum levels ; Substance-Related Disorders - blood ; Substance-Related Disorders - physiopathology ; Young Adult</subject><ispartof>Human psychopharmacology, 2018-05, Vol.33 (3), p.e2656-n/a</ispartof><rights>Copyright © 2018 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3106-54e1288372340985e94fb3c1d7d89a2bef063d669935bcc1b6b6dd0a162c896f3</cites><orcidid>0000-0003-3007-3174</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhup.2656$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhup.2656$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29602228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Minling</creatorcontrib><creatorcontrib>He, Hongbo</creatorcontrib><creatorcontrib>Ning, Yuping</creatorcontrib><creatorcontrib>Ding, Yi</creatorcontrib><creatorcontrib>Ke, Xiaoyin</creatorcontrib><creatorcontrib>Wang, Daping</creatorcontrib><creatorcontrib>Deng, Xuefeng</creatorcontrib><creatorcontrib>Fan, Ni</creatorcontrib><title>Low serum level of epidermal growth factor in chronic ketamine users</title><title>Human psychopharmacology</title><addtitle>Hum Psychopharmacol</addtitle><description>Background
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and psychopathological symptoms were analyzed.
Methods
Sixty‐seven chronic ketamine users and 40 healthy subjects were recruited. Serum EGF levels were measured by enzyme‐linked immunosorbent assay. Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale, Beck Depression Inventory and Beck Anxiety Inventory.
Results
The serum level of EGF in the chronic ketamine users was significantly lower than that of healthy subjects (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml, F = 15.169, p < 0.01). The serum EGF level was negatively correlated with the current average dose of ketamine consumption per day of use (p = 0.015), and positively associated with the Positive and Negative Syndrome Scale positive symptom score (p = .022).
Conclusions
Serum level of EGF decreased in chronic ketamine users compared with healthy subjects, which may play a role in the pathophysiology of ketamine related disorders.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anxiety</subject><subject>Demographics</subject><subject>Epidermal growth factor</subject><subject>Epidermal Growth Factor - blood</subject><subject>Excitatory Amino Acid Antagonists - adverse effects</subject><subject>Female</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Ketamine</subject><subject>Ketamine - adverse effects</subject><subject>Male</subject><subject>Mental depression</subject><subject>serum</subject><subject>Serum levels</subject><subject>Substance-Related Disorders - blood</subject><subject>Substance-Related Disorders - physiopathology</subject><subject>Young Adult</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1Lw0AQhhdRbK2Cv0AWvHhJnd0km92j1I8KBT3Yc0g2E5uaZOtuYum_d2urguBpYOaZZ4aXkHMGYwbArxf9asxFLA7IkIFSAYMkOSRDkDIOBOd8QE6cWwL4GahjMuBKgG_LIbmdmTV1aPuG1viBNTUlxVVVoG2ymr5as-4WtMx0ZyytWqoX1rSVpm_YZU3VIu39rjslR2VWOzzb1xGZ39-9TKbB7OnhcXIzC3TIQARxhIxLGSY8jEDJGFVU5qFmRVJIlfEcSxBhIYRSYZxrzXKRi6KAjAmupRJlOCJXO-_KmvceXZc2ldNY11mLpncpBw6RYqG_MSKXf9Cl6W3rv_NUlESQgIx_hdoa5yyW6cpWTWY3KYN0m2zqk023yXr0Yi_s8waLH_A7Sg8EO2Bd1bj5V5RO589fwk8WdIA5</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Zhang, Minling</creator><creator>He, Hongbo</creator><creator>Ning, Yuping</creator><creator>Ding, Yi</creator><creator>Ke, Xiaoyin</creator><creator>Wang, Daping</creator><creator>Deng, Xuefeng</creator><creator>Fan, Ni</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3007-3174</orcidid></search><sort><creationdate>201805</creationdate><title>Low serum level of epidermal growth factor in chronic ketamine users</title><author>Zhang, Minling ; He, Hongbo ; Ning, Yuping ; Ding, Yi ; Ke, Xiaoyin ; Wang, Daping ; Deng, Xuefeng ; Fan, Ni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3106-54e1288372340985e94fb3c1d7d89a2bef063d669935bcc1b6b6dd0a162c896f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anxiety</topic><topic>Demographics</topic><topic>Epidermal growth factor</topic><topic>Epidermal Growth Factor - blood</topic><topic>Excitatory Amino Acid Antagonists - adverse effects</topic><topic>Female</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Ketamine</topic><topic>Ketamine - adverse effects</topic><topic>Male</topic><topic>Mental depression</topic><topic>serum</topic><topic>Serum levels</topic><topic>Substance-Related Disorders - blood</topic><topic>Substance-Related Disorders - physiopathology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Minling</creatorcontrib><creatorcontrib>He, Hongbo</creatorcontrib><creatorcontrib>Ning, Yuping</creatorcontrib><creatorcontrib>Ding, Yi</creatorcontrib><creatorcontrib>Ke, Xiaoyin</creatorcontrib><creatorcontrib>Wang, Daping</creatorcontrib><creatorcontrib>Deng, Xuefeng</creatorcontrib><creatorcontrib>Fan, Ni</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Minling</au><au>He, Hongbo</au><au>Ning, Yuping</au><au>Ding, Yi</au><au>Ke, Xiaoyin</au><au>Wang, Daping</au><au>Deng, Xuefeng</au><au>Fan, Ni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low serum level of epidermal growth factor in chronic ketamine users</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum Psychopharmacol</addtitle><date>2018-05</date><risdate>2018</risdate><volume>33</volume><issue>3</issue><spage>e2656</spage><epage>n/a</epage><pages>e2656-n/a</pages><issn>0885-6222</issn><eissn>1099-1077</eissn><abstract>Background
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and psychopathological symptoms were analyzed.
Methods
Sixty‐seven chronic ketamine users and 40 healthy subjects were recruited. Serum EGF levels were measured by enzyme‐linked immunosorbent assay. Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale, Beck Depression Inventory and Beck Anxiety Inventory.
Results
The serum level of EGF in the chronic ketamine users was significantly lower than that of healthy subjects (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml, F = 15.169, p < 0.01). The serum EGF level was negatively correlated with the current average dose of ketamine consumption per day of use (p = 0.015), and positively associated with the Positive and Negative Syndrome Scale positive symptom score (p = .022).
Conclusions
Serum level of EGF decreased in chronic ketamine users compared with healthy subjects, which may play a role in the pathophysiology of ketamine related disorders.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29602228</pmid><doi>10.1002/hup.2656</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3007-3174</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-6222 |
| ispartof | Human psychopharmacology, 2018-05, Vol.33 (3), p.e2656-n/a |
| issn | 0885-6222 1099-1077 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2020491388 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adolescent Adult Anxiety Demographics Epidermal growth factor Epidermal Growth Factor - blood Excitatory Amino Acid Antagonists - adverse effects Female Growth factors Humans Ketamine Ketamine - adverse effects Male Mental depression serum Serum levels Substance-Related Disorders - blood Substance-Related Disorders - physiopathology Young Adult |
| title | Low serum level of epidermal growth factor in chronic ketamine users |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T15%3A43%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20serum%20level%20of%20epidermal%20growth%20factor%20in%20chronic%20ketamine%20users&rft.jtitle=Human%20psychopharmacology&rft.au=Zhang,%20Minling&rft.date=2018-05&rft.volume=33&rft.issue=3&rft.spage=e2656&rft.epage=n/a&rft.pages=e2656-n/a&rft.issn=0885-6222&rft.eissn=1099-1077&rft_id=info:doi/10.1002/hup.2656&rft_dat=%3Cproquest_cross%3E2047407085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2047407085&rft_id=info:pmid/29602228&rfr_iscdi=true |